Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial
published in: Journal of Clinical Oncology
date of publication: 2020-10-14
Cites articles
There is nothing here
Article - wd:Q100536554